Johnson & Johnson has a new dual-energy ablation platform, but will hospitals adopt it?
Find out how Johnson & Johnson’s dual-energy ablation system could reshape cardiac arrhythmia procedures.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
QT Imaging passed its first FDA inspection cleanly, but can adoption follow?
Find out how QT Imaging’s clean FDA inspection could support Breast Acoustic CT scale-up and breast imaging adoption.
Pharma & Biotech
Pharvaris has an FDA review date for deucrictibant, but can it stand out?
Find out how Pharvaris’ deucrictibant could reshape oral treatment options for hereditary angioedema attacks.
Medical Devices & Diagnostics
Presage Technologies SmartSpectra cleared for contactless vital signs monitoring
Find out how Presage Technologies’ SmartSpectra software uses phone cameras to measure pulse and breathing rate without sensors.
Pharma & Biotech
Can CoRegen’s CRG-150 turn regulatory T cells into a solid tumour weapon?
Find out how CoRegen is advancing CRG-150 into human trials for metastatic breast cancer, prostate cancer and solid tumours.
Medical Devices & Diagnostics
Can Movmedix turn LARS ACJ clearance into meaningful United States adoption?
Find out how Movmedix plans to launch its FDA-cleared LARS ACJ synthetic ligament system for severe shoulder joint injuries.
Pharma & Biotech
LTZ Therapeutics secures FDA clearance for LTZ-232 Phase 1 cancer trial
Find out how LTZ Therapeutics is advancing LTZ-232 into a Phase 1 trial targeting macrophages in metastatic colorectal cancer.
Pharma & Biotech
Alterity gains a streamlined FDA pathway as ATH434 faces its decisive clinical test
Alterity Therapeutics has secured an FDA-aligned Phase 3 pathway for ATH434 in multiple system atrophy, with one pivotal study potentially supporting an approval application.
Pharma & Biotech
Galderma’s relabotulinumtoxinA FDA setback shifts attention to manufacturing readiness
Discover why FDA manufacturing concerns have delayed Galderma’s relabotulinumtoxinA approval and what the company must resolve next.
Pharma & Biotech
FDA expands Skyrizi to children as AbbVie introduces weight-based 55 mg dose
AbbVie has secured a broad pediatric label for Skyrizi, adding both plaque psoriasis and active psoriatic arthritis alongside a new dose for children weighing less than 40 kg. The approval could strengthen treatment choice, although the evidence supporting the two indications is not equally direct.